Pembrolizumab and Doxorubicin Hydrochloride in Treating Patients With Sarcoma That is Metastatic or Cannot Be Removed by Surgery

NCT02888665 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Sarcoma

Interventions

DRUG: Doxorubicin Hydrochloride
OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Pembrolizumab

Sponsor

Fred Hutchinson Cancer Center

Collaborators

[object Object]